Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Roflumilast

A selective inhibitor of phosphodiesterase 4 (PDE4), an enzyme involved in inflammation, approved in Europe in 2010 and in the United States in 2011 as a tablet for severe COPD with chronic bronchitis. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards and other impurities.

Did you know?After the lungs it moved on to the skin: since 2022 the same molecule has been used as a cream, and later a foam, for psoriasis, seborrhoeic dermatitis and atopic dermatitis.

RoflumilastGo to the active ingredient →
RoflumilastActive ingredientRoflumilastCat. No. P-R080-001CAS 162401-32-3
Roflumilast-d3Isotopically labelledRoflumilast-d3Cat. No. P-R080-004CAS 1189992-00-4
Roflumilast-d4Isotopically labelledRoflumilast-d4Cat. No. P-R080-005CAS 1398065-69-4

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.